The Female Health Company To Present At 14th Annual B. Riley & Co. Investor Conference On May 20, 2013

May 15, 2013

CHICAGO, May 15, 2013 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO)  today announced that it will be presenting at the 14th Annual B. Riley & Co. Investor Conference on May 20, 2013.  

(Logo: http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

The conference is being held at the Lowes Santa Monica Beach Hotel, which is located at 1700 Ocean Avenue in Santa Monica, California.

The presentation by O.B. Parrish, Chief Executive Officer, and Michele Greco, Chief Financial Officer, is scheduled for 3:00 p.m. PDT (6:00 p.m. EDT) on Monday, May 20, 2013 in the Arcadia EF Room.

About the B. Riley & Co. Investor Conference

The prestigious three-day, invitation-only annual B. Riley & Co. Investor Conference brings together a targeted audience of leading institutional investors, financial services professionals and other qualified investors.  The conference will feature presentations by over 200 companies in a broad range of sectors, including technology, consumer, retail, energy, healthcare and financials.  One-on-one meetings with company managements will be available for all client investors.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 139 other countries globally.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about The Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com

SOURCE The Female Health Company

For further information: William R. Gargiulo, Jr. 231.526.1244, Michele Greco, CFO 312.595.9123